J Morote1, Á J Tabernero2, J L Álvarez-Ossorio3, J P Ciria4, J L Domínguez-Escrig5, F Vázquez6, J Angulo7, F J López8, R de La Iglesia9, J Romero10. 1. Departamento de Urología, Hospital Universitario Vall d'Hebron, Barcelona, España. Electronic address: jmorote@vhebron.net. 2. Departamento de Urología, Hospital Universitario La Paz, Madrid, España. 3. Departamento de Urología, Hospital Universitario Puerta del Mar, Cádiz, España. 4. Departamento de Oncología Radioterápica, Hospital Universitario Donostia, San Sebastián, España. 5. Departamento de Urología, Instituto Valenciano de Oncología, Valencia, España. 6. Departamento de Urología, Hospital Universitario Virgen de las Nieves, Granada, España. 7. Departamento de Urología, Hospital Universitario de Getafe, Madrid, España. 8. Departamento de Oncología Radioterápica, Hospital Universitario Virgen de la Arrixaca , Murcia, Spain. 9. Departamento de Urología, Hospital Rafael Méndez, Murcia, España. 10. Hospital Universitario Sant Joan d'Alacant, Alicante, España.
Abstract
OBJECTIVE: To assess the effect of androgen deprivation therapy (ADT) on cognitive performance (CP) in patients with prostate cancer (PCa) after 6 months of treatment with luteinizing hormone-releasing hormone (LHRH) analogues. MATERIAL AND METHODS: Prospective, observational, multicentre, open-label study of patients diagnosed with nonmetastatic or asymptomatic metastatic PCa scheduled to receive LHRH analogues for≥6 months. We assessed four CP domains at baseline and after 6 months of ADT: 1) Working memory: Wechsler Adult Intelligence Scale III (WAIS III) Digit Span Subtest (WAIS III-Digit); 2) Visual memory: ad hoc visual memory test; 3) Visuospatial ability: Judgement of Line Orientation (JLO) and Mental Rotation of Three-Dimensional Objects (3D-Rotation); and 4) Nonverbal analytical reasoning: WAIS III Matrix Reasoning Test (WAIS III-MRT). Changes outside the baseline 95% confidence intervals were considered significant. RESULTS: A total of 308 patients completed the study. Of these, 245 (79.6%) experienced no statistically significant changes on any test and 63 patients (20.4%) experienced significant changes in ≥1 test. Of these, most presented a change in only one test, distributed evenly between improvements (58 patients; 18.8%) and worsening (56 patients; 18.2%). For individual tests, most patients (87.8% to 91.8%) had no change from baseline; however, the significant changes (improvement vs. deterioration, respectively) were as follows: WAIS III-Digit (6.3% vs. 5.9%); visual memory (5.3% vs. 5.7%); JLO (5.3% vs. 4.5%); 3D-Rotation (4.1% vs. 4.1%); and WAIS III-MRT (4.8% vs. 5.8%). CONCLUSIONS: CP in patients with PCa does not appear to be adversely affected by 6 months of LHRH analogue administration.
OBJECTIVE: To assess the effect of androgen deprivation therapy (ADT) on cognitive performance (CP) in patients with prostate cancer (PCa) after 6 months of treatment with luteinizing hormone-releasing hormone (LHRH) analogues. MATERIAL AND METHODS: Prospective, observational, multicentre, open-label study of patients diagnosed with nonmetastatic or asymptomatic metastatic PCa scheduled to receive LHRH analogues for≥6 months. We assessed four CP domains at baseline and after 6 months of ADT: 1) Working memory: Wechsler Adult Intelligence Scale III (WAIS III) Digit Span Subtest (WAIS III-Digit); 2) Visual memory: ad hoc visual memory test; 3) Visuospatial ability: Judgement of Line Orientation (JLO) and Mental Rotation of Three-Dimensional Objects (3D-Rotation); and 4) Nonverbal analytical reasoning: WAIS III Matrix Reasoning Test (WAIS III-MRT). Changes outside the baseline 95% confidence intervals were considered significant. RESULTS: A total of 308 patients completed the study. Of these, 245 (79.6%) experienced no statistically significant changes on any test and 63 patients (20.4%) experienced significant changes in ≥1 test. Of these, most presented a change in only one test, distributed evenly between improvements (58 patients; 18.8%) and worsening (56 patients; 18.2%). For individual tests, most patients (87.8% to 91.8%) had no change from baseline; however, the significant changes (improvement vs. deterioration, respectively) were as follows: WAIS III-Digit (6.3% vs. 5.9%); visual memory (5.3% vs. 5.7%); JLO (5.3% vs. 4.5%); 3D-Rotation (4.1% vs. 4.1%); and WAIS III-MRT (4.8% vs. 5.8%). CONCLUSIONS: CP in patients with PCa does not appear to be adversely affected by 6 months of LHRH analogue administration.
Authors: Daniel J Tobiansky; Kathryn G Wallin-Miller; Stan B Floresco; Ruth I Wood; Kiran K Soma Journal: Front Endocrinol (Lausanne) Date: 2018-06-05 Impact factor: 5.555
Authors: Cornelie D Andela; Rafil Matte; Ingrid M Jazet; Willemijn Cg Zonneveld; Jan W Schoones; A Edo Meinders Journal: Int J Urol Date: 2021-06-14 Impact factor: 2.896